Still holding a nice slug of cash, but that's evaporating quickly. Revenues all but disappeared and only nearer term hope is a launch in 2014 which is iffy and who's to say if they get to market they'll have any success with sales. Nice short opportunity for the remainder of the year as reality settles in.
You might be right, but then again we can't discount the implication of an FDA approval for MNTA;s ANDA of copaxane which, good or bad, should certainly come before the year ends. This will move the stock upward imo.
While it might be true that there is no givens regarding sales in 2014, Id hardly bet against Navartus/Sandoz if the FDA does give them approval.
Furthmore I don't believe that Teva's effort to preserve their revenue stream by creating a 3x a week dose vs a daily dose will be able to materialize the preservation of their revenue they way they intend it to. net net.. upside from here even if we see a little pullback still.
Momenta with all its talk, has yet to be convincing that they are working closely with the FDA for any Copaxone ANDA approval, while I'am sure conversations have been had seams non productive. Will they say the same thing in 2014?